My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 433

    1.

    Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

    Rossing K, Christensen PK, Jensen BR, Parving HH.

    Diabetes Care. 2002 Jan;25(1):95-100.PMID: 11772908 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.

    Nephrol Dial Transplant. 2002 Jun;17(6):1019-24.PMID: 12032191 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.

    Kidney Int. 2003 May;63(5):1874-80.PMID: 12675866 [PubMed - indexed for MEDLINE]Related articles

    4.

    Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.

    Rossing K, Jacobsen P, Pietraszek L, Parving HH.

    Diabetes Care. 2003 Aug;26(8):2268-74.PMID: 12882847 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.

    Jacobsen P, Andersen S, Jensen BR, Parving HH.

    J Am Soc Nephrol. 2003 Apr;14(4):992-9.PMID: 12660333 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

    Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH.

    Diabetes Care. 2005 Sep;28(9):2106-12.PMID: 16123474 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.

    Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH.

    Diabetes. 1997 Mar;46(3):481-7.PMID: 9032106 [PubMed - indexed for MEDLINE]Related articles

    8.

    Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.

    Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH.

    Diabetes Care. 2003 Jan;26(1):150-5.PMID: 12502672 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.

    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.

    Clin Nephrol. 2003 Nov;60(5):318-26.PMID: 14640237 [PubMed - indexed for MEDLINE]Related articles

    10.

    Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.

    Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.

    Diabetes Care. 2000 Dec;23(12):1725-30.PMID: 11128341 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.

    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.

    Nephrol Dial Transplant. 2006 Mar;21(3):683-9. Epub 2005 Dec 5.PMID: 16330466 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.

    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.

    Kidney Int Suppl. 2002 Dec;(82):S47-52.PMID: 12410855 [PubMed - indexed for MEDLINE]Related articles

    13.

    Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.

    Kidney Int. 2000 Feb;57(2):601-6.PMID: 10652037 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.

    Christensen PK, Lund S, Parving HH.

    Kidney Int. 2001 Oct;60(4):1435-42.PMID: 11576357 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.

    Krairittichai U, Chaisuvannarat V.

    J Med Assoc Thai. 2009 May;92(5):611-7.PMID: 19459520 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.

    Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA.

    Clin Nephrol. 2005 Sep;64(3):180-9.PMID: 16175942 [PubMed - indexed for MEDLINE]Related articles

    17.

    The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

    Nephrol Dial Transplant. 2000 Apr;15(4):487-97.PMID: 10727543 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)]

    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.

    Dtsch Med Wochenschr. 2001 May 11;126(19):547-50. German. PMID: 11402910 [PubMed - indexed for MEDLINE]Related articles

    19.

    Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

    Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH.

    Kidney Int. 2006 Aug;70(3):536-42. Epub 2006 Jun 14.PMID: 16775595 [PubMed - indexed for MEDLINE]Related articles

    20.

    Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

    Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators.

    Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. Epub 2008 May 1.PMID: 18450829 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity